About DUB Therapeutics
Pioneering innovative therapeutics to restore vision and transform lives
Our Mission
To bring global relief and increased quality of life to patients living with fibrosis. We're pioneering self-delivering RNA therapeutics that target the root causes of tissue scarring, starting with critical unmet needs in ocular surface diseases and expanding to address fibrotic conditions across multiple therapeutic areas.
Our Vision
To become the leading innovator in anti-fibrotic therapeutics, leveraging our proprietary sdRNA platform to unlock new treatment possibilities for patients worldwide. We envision a future where fibrosis—a major contributor to disease burden—is no longer "undruggable."
Our Core Values
The principles that guide our work and define our culture
Scientific Excellence
Rigorous research and evidence-based development drive every decision we make.
Patient First
Every innovation is designed with patient needs, safety, and accessibility at the forefront.
Innovation
We challenge conventional approaches to create breakthrough solutions for unmet medical needs.
Our Story
Founded in March 2022, DUB Therapeutics was incorporated following decades of pioneering scientific research. Our scientific foundation is built on the discovery of a novel class of enzymes whose activity controls protein degradation and influences the stages of wound healing to promote tissue regeneration.
We've developed a proprietary self-delivering siRNA (sdRNA) platform that targets these critical pathways. Our lead programs focus on ocular surface diseases where the cornea's unique biology—a highly organized tissue that must maintain transparency for functionality—presents opportunities for the development of breakthrough treatments.
In 2023, our work gained significant recognition with a $2M USD NIH SEED grant to advance the first ophthalmology program. This support significantly advanced our regulatory development culminating in the completion of an FDA INTERACT meeting December 2024. In early 2025, the completion of these milestones led to a $1M USD investment by Upstate Biotech Ventures and a second Direct to Phase II NIH grant for the second ophthalmology program in development.
While our current focus addresses critical unmet needs in ophthalmology, our vision extends to the broader landscape of fibrotic diseases affecting patients worldwide. We're advancing multiple programs through pre-clinical development with clinical trials planned for 2027, as we work to transform what was once considered "undruggable" targets into conditions treatable with sdRNA technology.